Weight Loss

From regulating appetite to improving blood sugar control, GLP-1 drugs like Ozempic are emerging as powerful metabolic tools at a time when India urgently needs better solutions

Ozempic debuts in India at ₹2,200 per week, offering a new treatment option for type 2 diabetes as demand grows for effective and easy-to-use metabolic health therapies

The approval marks a major win for Sun Pharma in its patent dispute with Danish drugmaker Novo Nordisk, the company that manufactures weight loss drug Ozempic

The deal marks Healthify's first such partnership with a drugmaker, and it hopes similar agreements will boost its paid subscriber base

Australia has issued a safety alert on GLP-1 drugs after reviewing reports of depression and suicidal thoughts; while there is no proven causal link, regulators want users to stay alert

The guideline reframes obesity as a chronic disease needing lifelong care, recommending GLP-1 therapies with behavioural support rather than relying on medication alone

A new clinical trial shows that kalonji, long used in Indian kitchens, may help lower cholesterol and slow fat formation, offering a natural metabolic boost alongside regular diet and lifestyle habits

As GLP-1-based weight-loss and diabetes therapies gain popularity, India's diagnostics market is seeing a sharp rise in metabolic testing

Research suggests GLP-1 injections like Ozempic and Zepbound may dampen alcohol and drug cravings by lowering dopamine reward responses, but larger human trials are still underway

A Yale study suggests GLP-1 drugs like semaglutide slow alcohol breakdown in the liver, raising blood alcohol levels even as they reduce toxic byproducts linked to inflammation and liver damage

Novo Nordisk will strengthen its oral semaglutide portfolio led by Rybelsus while cutting Wegovy injection prices by up to 37% to improve accessibility and expand its market in India

World Diabetes Day 2025: Experts say shifting from high-GI staples to low-GI grains can help steady blood sugar, curb cravings, improve satiety, and support weight control with simple grain rotation

Move comes in a bid to gain more space in India's anti-obesity market dominated by Mounjaro

Advances in obesity and metabolism research may mean that future therapies can be able to turn down these signals that drive the body back to its original weight, even beyond the treatment period

The deal will help expand the availability and marketing of this weight-loss medicine, especially in areas where Novo Nordisk's reach is limited

Marketed as a herbal weight-loss supplement, Molecule has gone viral on Russian TikTok but contains a banned drug linked to heart attacks, anxiety, and hospitalisations among teenagers

From balanced home meals to fun, everyday activities, here's how you can ease back into fitness and lose festive weight sustainably.

A new review highlights how anti-obesity drugs like semaglutide and tirzepatide may help reverse fat build-up, inflammation, and scarring in patients with MASLD and MASH

Novo Nordisk's Ozempic launch adds to its GLP-1 portfolio, offering patients new options while competing with Eli Lilly's Mounjaro in India

Those at the lower end of the "healthy" range also faced higher risks, with BMIs between 18.5 and 19.9 doubling the likelihood of death